Answers are grounded in this paper and cite their sources.
A prospective cohort study was conducted to evaluate long-term safety of tedizolid as suppressive antimicrobial treatment in patients with implant-associated bone and joint infection caused by multidrug-resistant gram-positive pathogens. Seventeen patients received tedizolid with a median duration of treatment of 6 months. No patients developed a serious adverse event.
No takes yet. Share an insight, caveat, or question.
Ferry et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: